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Dietary preferences and nutrients composition have been shown to inﬂuence human and
gut microbial metabolism, which ultimately has speciﬁc effects on health and diseases’
risk. Increasingly, results from molecular biology and microbiology demonstrate the key
role of the gut microbiota metabolic interface to the overall mammalian host’s health sta-
tus. There is therefore raising interest in nutrition research to characterize the molecular
foundations of the gut microbial–mammalian cross talk at both physiological and biochem-
ical pathway levels. Tackling these challenges can be achieved through systems biology
approaches, such as metabolomics, to underpin the highly complex metabolic exchanges
between diverse biological compartments, including organs, systemic bioﬂuids, and micro-
bial symbionts. By the development of speciﬁc biomarkers for prediction of health and
disease, metabolomics is increasingly used in clinical applications as regard to disease
etiology, diagnostic stratiﬁcation, and potentially mechanism of action of therapeutical and
nutraceutical solutions. Surprisingly, an increasing number of metabolomics investigations
in pre-clinical and clinical studies based on proton nuclear magnetic resonance (1H NMR)
spectroscopy and mass spectrometry provided compelling evidence that system wide
and organ-speciﬁc biochemical processes are under the inﬂuence of gut microbial metab-
olism. This review aims at describing recent applications of metabolomics in clinical ﬁelds
where main objective is to discern the biochemical mechanisms under the inﬂuence of
the gut microbiota, with insight into gastrointestinal health and diseases diagnostics and
improvement of homeostasis metabolic regulation.
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SYSTEM BIOLOGY APPROACHES TO DECIPHER THE
COMPLEX METABOLIC NETWORKS OF MAMMALIAN
ORGANISMS
Recent advances in nutrition research aims at determining and fur-
ther our understanding on the biochemical effects of nutrients and
foods in order to promote beneﬁcial nutritional and health status
at individual and population level. In this, the mammalian gut
microbial relationship is a key determinant by performing multi-
ple digestive, immune, and metabolic functions (Nicholson et al.,
2005; Dethlefsen et al., 2007; Ley et al., 2008). The gastrointestinal
tract of adult humans contain around 1.5 k of biomass composed
by gut microbial symbiotic and commensal organisms that are in
intimate communication with the host, which is the result of a
long period of co-adaptation between the host genotype and the
gut microbiome (Gill et al., 2006). The gut microbiota provides
to the host speciﬁc capacities ranging from dietary energy recov-
ery from nutrients, generating digestible carbohydrates and short
chain fatty acids (SCFAs) from otherwise non-digestible ﬁbers,
amino acids, and vitamins, to protection against infectious dis-
eases (Cummings et al., 1987; Gilmore and Ferretti, 2003; Xu
et al., 2003; Tannock, 2005). Gut microbial activities were shown
to be extremely speciﬁc, as exempliﬁed via its essential role in the
development andmaintenance of themucosal innate and adaptive
immune system (Guigoz et al., 2008). In parallel, there is increasing
awareness that many health disorders involve a signiﬁcant pertur-
bation of immune and energy metabolism which are intrinsically
linked to the gut functionally ecology (Dunne, 2001; Turnbaugh
et al., 2006; Dethlefsen et al., 2007).
The consortium of symbiotic gut microorganisms can be
viewed as a metabolically adaptable, rapidly renewable, and meta-
bolically ﬂexible ecosystem varying in addition with the host’s age,
diet, and health status. Consequently, the microbiome is a nutri-
tional target today andmight also become the foundation of future
drug targeting and interventions (Jia et al., 2008). Systems biology
approaches have emerged over the last two decades as a novel way
forward to provide insights into the role of mammalian gutmicro-
bial metabolic interactions in individual susceptibility to health
and disease outcomes. In particular, metabolomics offers new
opportunities to explore individual needs, foods, and nutrients
functionalities and formulate tangible biological hypotheses that
can be followed-up and tested at individual and population scale.
Nowadays,metabolomics is based on the quantitativemeasure-
ment of dynamic metabolic changes of living systems in response
to genetic modiﬁcations or physiological stimuli, including nutri-
ents, and drugs. Metabolites are the products and by-products of
the many intricate biosynthetic and catabolic pathways existing in
all living systems. Therefore, monitoring the resulting metabolic
variations provides a unique insight into intra- and extra-cellular
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FIGURE 1 | Conceptualization of nutritional metabonomics for
gastrointestinal health and risk management.The metabolic status of
individuals results from gene, environment, lifestyle, food, and gut
microbiota continuous interactions. The relationship between host and gut
microbiota, with the metabolic inﬂuence of gut symbionts at different level
of biological organization, underpins the depth of symbiotic control over
multiple host cell metabolic regulatory functions.
regulatory processes involved in our metabolic homeostasis. By
the study of lowmolecular weight compounds in bioﬂuids (blood
and urine), stools, and tissues (intact biopsies or extracts; Beck-
onert et al., 2010), metabolomics assures the characterization of
metabolic ﬁngerprints that can be associated with individual phe-
notypes, which encompass dietary or disease status (Figure 1).
Metabolomics employs mainly two analytical techniques based on
1H nuclear magnetic resonance (NMR) spectroscopy, and mass
spectrometry (MS).MSmethods are also commonly employed for
global and targeted proﬁling and are inherentlymore sensitive, but
require a more comprehensive sample preparation (Bruce et al.,
2009) with separation of the metabolites components using either
gas chromatography (GC) or liquid chromatography (LC). Both
methods are then comprehensively used to generate high density
data, fromwhichmeaningful biological information are recovered
using advanced statistical tools (Eriksson et al., 2004; Montoliu
et al., 2009). One recent analytical revolution – lipidomics –
now enables the elucidations of molecular processes that involve
the disruption of lipid metabolic enzymes and pathways. State-
of-the art methods for characterizing the lipidome encompasses
non-targeted proﬁling approach using a global shotgun approach
(Ejsing et al., 2009), or alternatively, main lipid category sepa-
ration using LC–MS approaches (Pietilainen et al., 2007). The
emergence of “Nutrimetabolomics” illustrates the mutual link
among nutrition andmetabolomics research to study the effects of
speciﬁc ingredients and food components elucidating themolecu-
lar mechanisms behind individual metabolic responses. However,
deciphering food-induced metabolic reactions is very challeng-
ing since they vary greatly among individuals as differences in
endogenous factors such as diet, stress, age, environment, genetics,
lifestyle, and gutmicrobiota. Inparticular, recent advances in cellu-
lar andmolecular biology have provided compelling evidence that
the intestinal microbiota contribution to the overall health status
of the host has been underestimated so far. Both system wide (i.e.,
whole organism) and organ-speciﬁc changes in metabolic proﬁles
may have components indeed driven by gut microbial activities
(Nicholson et al., 2005; Zheng et al., 2011). This review there-
fore aims at describing current advances in metabolomic studies
where main objective is to discern the molecular pathways and
mechanisms under the inﬂuence of gut microbial metabolism in
the context of gastrointestinal diseases. Furthermore, emphasis
is given to nutritional approaches, where the quest for home-
ostatic balance is dependent not only on the host but also on
the nutritional modulation of the gut microbiota–host metabolic
interactions.
GUT FLORA AND HOST METABOLISM
The gastrointestinal tract is a complex ecosystem host to a diverse
and highly evolved microbial community composed of hundreds
of different microbial species. The human body contains circa 10
trillion parenchymal cells, but the gut contains approximately 100
trillion of microbial organisms,which vary in community compo-
sition through life according to lifestyle and nutrition (Beale, 2002;
Xu and Gordon, 2003; Tannock, 2005; Xu et al., 2007). Increasing
scientiﬁc evidence has been reported on the fundamental role of
gut microbiota in both positive and negative triggers of speciﬁc
metabolic states of individuals and populations (Dunne, 2001;
Verdu et al., 2004; Backhed et al., 2005; Gill et al., 2006). There-
fore, it is today critical to understand the molecular foundations
of the impact of the gut microbial activity on human health and
nutritional status. For instance, mammalian–microbial symbio-
sis can be inﬂuential in the etiology and development of several
diseases, including metabolic syndrome (Ley et al., 2006), insulin
resistance (Dumas et al., 2006), inﬂammatory bowel disease (IBD;
Gupta et al., 2000), irritable bowel syndrome (IBS; Sartor, 2004),
and gastrointestinal cancers (Dunne, 2001).
Both system wide (i.e., whole organism) and organ-speciﬁc
changes in metabolic proﬁles may have components driven by
gut microbial activities (Martin et al., 2009a, 2010a). The current
omics revolution offers an unprecedented opportunity to explore
how our gut symbionts contribute to our physiology and how they
can be exploited to develop new therapeutic and nutritional strate-
gies. Optimal systems biology approaches lies in the combination
of state-of-the-art microbial and metabolic monitoring and dis-
covery approaches, including metagenomics and metabolomics.
In particular, rRNA and metagenomic sequencing offers novel
means to decipher the content, diversity, and functioning of the
microbial gut community, with the ultimate aims to help further
the understanding of the impact of the gut microbes on human
health (Qin et al., 2010). Recently, Qin et al. (2010) reported an
exhaustive gene catalog containing virtually all of the prevalent
gut microbial genes in large human cohort, and reported to which
extent many bacterial species are shared by different individu-
als. Moreover the authors also pinpointed how such an approach
could be used for global characterization of the genetic potential
of ecologically complex environments (Qin et al., 2010).
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Recently, applications of top-down system biology approaches
described the depth and width of gut microbial inﬂuence on host
metabolic functions, resulting in modulation of host lipid, carbo-
hydrate, and amino acid metabolism at organ and system levels
(Martin et al., 2009a; Claus et al., 2011; Merriﬁeld et al., 2011;
Mestdagh et al., 2011). For instance, the speciﬁc metabolic activi-
ties of a single gut bacterial species can provide the host with new
biochemical compounds in sufﬁcient amount to be detected in the
general blood circulation (Wikoff et al., 2009). Martin et al. exem-
pliﬁed how the gut microbial modulation of the gastrointestinal
system (Martin et al., 2009b) and extensivemicrobial–mammalian
co-metabolism may ﬁne-tune host metabolic processes and may
induce metabolic deregulations (Martin et al., 2007a). In particu-
lar, the authors highlighted the different bacterial modulation of
the bile acidmetabolism and enterohepatic cycle, with consequent
effects on the absorption of dietary fat and concomitant to lipid
accumulation in the livers of animals harboring a non-adapted gut
microbiota. In these investigations, the gut microbiota exerts deep
and long-range control over multiple host cell metabolic path-
ways impacting on health and nutritional outcomes (Martin et al.,
2007a; Clayton et al., 2009) via, for instance, the co-metabolism of
bile acids and inferred modulation of lipid and cholesterol metab-
olism (Swann et al., 2011). Together, these studies suggest that
controlling the dynamics of the gut microbiome to maintain or
re-establish a balanced and well-adapted microbiota could help
in preventing some microbial-related metabolic disorders, such as
hepato-gastrointestinal diseases.
THE ROLE OF GUT MICROBES IN DETERMINING
GASTROINTESTINAL FUNCTIONAL ECOLOGY
The intestinal tract is one of themost important interface between
mammalian metabolism and the environment along which the
varying metabolic activities of the gut microbiota not only
determine absorption, digestion, metabolism, and excretion of
dietary nutrients but also shape regio-speciﬁcally the surround-
ing and distant host cell biochemical processes (Hooper et al.,
2002). Advances in metabolomic applications are providing novel
insights into the molecular foundations of these host–microbial
relationships and their inﬂuence onto health and disease risks
(Martin et al., 2009b, 2010b). In particular, a series of investi-
gations in humans (Wang et al., 2007), rats (Wang et al., 2005),
and gnotobiotic mice (Martin et al., 2007b, 2009b) have provided
a set of reference metabolic proﬁles of gut intestinal biopsies that
can be used not only to assess compartment structure and func-
tion but also the gut microbial impact at the tissue level (Martin
et al., 2007b). These studies therefore indicated that the type of gut
microbiota may be a key factor in the determination of the intesti-
nal homeostasis, osmo-protection, motility, and calorie recovery
from the diet. For instance, the ileum is regarded as the major site
for absorption of luminal bile acids and emulsiﬁed dietary lipids,
and the report of higher concentrations of glycerophospholipids,
glutathione, taurine, and betaine in this tissue was consistent with
its role in lipid and bile acid metabolism. The jejunum of the mice
harboring a non-adapted microbiota showed metabolic similar-
ities to the ileal proﬁle, marked by higher levels of glutathione,
and lower concentrations of its precursors in γ-glutamyl cycle
when compared to conventional animals. Such an observation
illustrates the essential role of the gut microbiota to inﬂuence sur-
rounding tissue metabolic pathways, to ultimately shape a host
environment that fosters their implantation and persistence. The
investigations also provided evidence that microbial-dependent
variations along the upper intestine were observed, which is often
underestimated due to low bacterial populations. These signatures
described that the type of gut bacteria affects the utilization efﬁ-
ciency of dietary proteins and amino acids and their subsequent
availability to extra-intestinal tissues.
METABOLOMICS APPLICATIONS TO INFLAMMATORY
BOWEL DISORDERS: IBD, IBS, AND CELIAC DISEASE
The inﬂuence of the gut microorganisms in the progression of
human diseases is nowadays a main concern in the etiology
and/or maintenance of gut dysfunctions, such as IBS (Madden
and Hunter, 2002) or IBD (Bickston et al., 2003). The incidence
andprevalence of IBDcontinue to riseworldwide and are the cause
of much morbidity and disability (Loftus Jr., 2004). The clinically
deﬁned and idiopathic forms of IBD) encompassing ulcerative
colitis (UC) and Crohn’s disease (CD), are spontaneously relaps-
ing and immunologically mediated chronic disorders of the gas-
trointestinal tract (Shanahan, 2001; Bickston et al., 2003). Both
manifestations are mediated by common and distinct mecha-
nisms inﬂuenced by multiple environmental factors and speciﬁc
genetic predispositions. Moreover, the involvement of gut micro-
biota in the chronic mucosal immune activation underlying the
IBD pathogenesis have been widely documented, in particular as
a key component in the duration and the prevention/treatment
of chronic intestinal inﬂammation (Swidsinski et al., 2002; Sartor,
2004; Haller, 2006). Advancing knowledge regarding the mecha-
nisms of IBD has led to the development of different therapeutic
solutions based on surgery (Harper et al., 1983; Korelitz et al.,
1985), cannabinoids (Duncan et al., 2005), immunosuppression
(Remicade, Mesalamine, etc.; Siemanowski and Regueiro, 2007;
Actis et al., 2008), and alternatively probiotic supplementation
(Reid et al., 2003). However, the IBD diagnosis is only possible at
an advanced disease state when symptoms are detectable by radi-
ology, endoscopy with biopsy of pathological lesions (Ahmadi and
Polyak, 2007). There is therefore a need to develop new strategies
for early prognosis and treatment of IBD.
There is increasing awareness in gastrointestinal science
for the prognostic, diagnostic, and monitoring potential of
metabolomics, as well as the opportunity to provide new insights
into IBD pathogenesis (Lin et al., 2011). A consistent approach
to deﬁne early biomarkers of pathogenesis to be used for disease
surveillance is the comprehensive analysis of the real endpoints
of physiological regulatory processes, the metabolites, which
may be associated with different IBD determinants. Winterkamp
et al. (2002) reported previously how N -methylhistamine, a key
metabolite in mast cell metabolism involved in the pathogene-
sis of IBD, could be used as an indicator of disease activity in
patients. Mast cells are indeed present all along the gastrointesti-
nal tract within all layers of the gut wall, and may inﬂuence acute
and chronic inﬂammation episodes (IBD, celiac disease, infectious
diarrheas) by releasing an array of mediators. Functional studies
revealed the release of elevated amounts of mast cell mediators
such as histamine and tryptase in the intestinal mucosa as well as
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increased levels of histamine in the gut lumen of patients with IBD,
both indicating a local up-regulation of mast cells in these inﬂam-
matory conditions of yet unknown origin (Winterkamp et al.,
2002). In this study the urinary excretion of N -methylhistamine
was associated with elevated histamine production and metabo-
lism in CD and UC, and could be used as a reliable diagnostic tool
to monitor clinical and endoscopic disease activity in IBD.
Metabolomics was also proven to be a valuable diagnostic tool
to differentiate CD from UC, but also active and quiescent UC, as
per the analysis of intact gut biopsies and colonocytes (Bezabeh
et al., 2001; Bjerrum et al., 2010). These studies showed that the
metabolic proﬁles of biopsies and colonocytes can be used to dif-
ferentiate active UC from controls. In the biopsies from patients
with active UC, higher concentrations of glutathione and of a
range of amino acids were associated with lower levels of lipid,
glycerophosphocholine, myo-inositol, and betaine. The changes
in glycerophospholipids and inositol were further conﬁrmed in
colonocytes studies. The authors also described that 20% of inac-
tive UC patients had similar proﬁles to those who were in an active
state. This study demonstrates the possibilities of metabolomics
as a diagnostic tool in active and quiescent UC and provides new
insight into pathophysiologicalmechanisms. In addition,Williams
et al. (2009) demonstrated how urinary metabolic proﬁling could
be employed to distinguish between CD from UC, which is crit-
ical for disease management. The most discriminant metabolites
included hippurate, 4-cresol sulfate, and formate, which are well
known for their gut microbial co-metabolism origin (Marchesi
et al., 2007). In CD, UC, and controls, there is a gradual decrease
in the concentration of aromatic metabolites, respectively, whilst
formate gradually increased.
These metabolomics observations are in agreement with other
studies where stool microbial and metabolic composition was
investigated in gastrointestinal diseases. All together, the moni-
toring of the fecal metabolome was proven to be of relevance to
unravel diagnostic information for IBD (Marchesi et al., 2007).
Such measurable outcomes provide some essential insights – yet
limited – into a small range of microbial activities within the
colon.Marchesi et al. (2007) described the ﬁrst characterization of
fecal extracts of IBD patients using metabolomics as a diagnostic
tool for differentiating patients affected with UC and CD, hence
improving disease surveillance. The fecal extracts of both CD
and UC patients were characterized by reduced levels of butyrate,
acetate, methylamine, and trimethylamine in comparison with a
control population, suggesting changes in the gut microbial com-
munity.Also, elevated quantities of amino acidswere present in the
feces from both disease groups, implyingmalabsorption caused by
the inﬂammatory disease or an element of protein losing enteropa-
thy. Furthermore, glycerol resonances were a dominant feature of
fecal spectra from patients with CD but were present in much
lower intensity in the control and UC groups. Recently, Le Gall
et al. (2011) described through metabolomics analysis of fecal
extracts combined with microbial proﬁling the alteration of both
population and metabolic activity of the gut microbiota in UC
and IBS. The authors followed-up a populations of healthy con-
trols, IBS, and UC patients over a period of 4 years. NMR-based
metabolomics resulted in a good prediction of UC against con-
trols, but could not discriminate robustly enough IBS from the
two other conditions. Whereas the fecal excretion of SCFAs and
amino acids remain stable across the groups, strong differences
were detected in the content of taurine, cadaverine, bile acid, and
branched chain fatty acids. The difference in the metabolic pro-
ﬁles observed in fecal water extracts of UC and healthy controls
was correlated with the distinct difference in the composition of
the gut microbiota, and demonstrate relationships between the
disease state and the handling of dietary lipids. Jansson et al.
(2009) also illustrated the potential of ion cyclotron resonance
Fourier transform MS (ICR-FT/MS) to determine the contribu-
tion of metabolites produced by the gutmicrobiota toward disease
status of the host via fecal monitoring. Biochemical pathways
involved in the metabolism and or synthesis of amino acids, fatty
acids, bile acids, and arachidonic acid were also highlighted in
colonic and ileal CD patients. Hong et al. (2010) reported the
use of fecal metabolomics to assess the effects of lactic acid pro-
biotic in a mouse model of acute colitis induced with dextran
sulfate sodium (DSS). DSS treatment was associated with a signif-
icant decrease of several amino acids, as well as butyrate, uracil,
and hypoxanthine. These changes were correlated with increases
of monosaccharides, glucose, and trimethylamine in the feces.
Histological damage, myeloperoxidase activity, and malondialde-
hyde content of colon tissue were reduced, whereas colon length
increased in mice supplemented with the probiotics. Interestingly,
the probiotic preventive treatment resulted in increased levels of
acetate, butyrate, and glutamine and decreased levels of trimethy-
lamine concomitant to the protective effects against DSS-induced
colitis, which suggests the modulation of the gut microbiota is of
importance.
A large majority of studies have focused on UC in different
animal models by exploring plasma (Schicho et al., 2010), urine
(Murdoch et al., 2008; Lin et al., 2010; Schicho et al., 2010; Otter
et al., 2011), and biopsies (Balasubramanian et al., 2008; Sharma
et al., 2010). However,most of the studies describe metabolic phe-
notypes at an advanced disease state when symptoms can already
be diagnosed by endoscopy. Recent applications on the monitor-
ing of metabolic alterations before and during the development
of the disease were reported in pre-clinical studies, and suggest
that metabolomics might help to deﬁne early IBD biomarkers.
Metabolomics was also successfully applied to studying UC asso-
ciated metabolism, using blood plasma (Martin et al., 2009c) or
urine (Murdoch et al., 2008) metabolic proﬁling. In both studies,
the gradual development of colitis was monitored from the age of
1 up to 24weeks using Interleukin 10 deﬁcient (IL-10−/−) mice
in combination with histopathology analyses. Overall, chronic
inﬂammation appears from 8weeks onward, and was associated
with altered cecum and colonmorphologies and increased inﬂam-
matory cell inﬁltration into themucosa and the submucosa. Blood
plasma metabolic proﬁling showed marked energy homeostasis
loss with impaired metabolism of lipoproteins and glycosylated
proteins (Martin et al., 2009c). In particular, IL-10−/− mice were
characterized by decreased levels of VLDL and increased concen-
trations of LDL and polyunsaturated lipids, which are related to
the etiology of IBD. Moreover, higher levels of lactate, pyruvate,
citrate, and lowered concentration of circulating glucose sug-
gested increased fatty acid oxidation and glycolysis. In addition,
UC was associated with higher plasma levels of free amino acids
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that can reﬂect increased muscle atrophy protein breakdown and
use of amino acids as metabolic fuel. Moreover, after week 8, the
IL-10 gene-deﬁcient mice also showed major urinary metabolic
differences with marked increased concentrations of fucose and
metabolites modulated by the gut microbiota, namely trimethy-
lamine and trimethylamine-N -oxide, as well as a decreased in
Krebs cycle intermediates (Murdoch et al., 2008). The authors sug-
gested that the increased urinary fucose excretion could be related
to the lower incorporation of fucose into red blood cell mem-
branes and subsequent increased serum concentration associated
with glycoproteins. Alternatively, the changes in urinary fucose
excretion could be associated with changes in the gut microﬂora
modulation of novo production of fucose for fucosylated glycans.
Recently, Baur et al. (2011) monitored the effects and con-
sequences of inﬂammatory processes associated with the grad-
ual evolution of CD-like ileitis on the local metabolism taking
advantage of TNFΔARE/WT mice. The TNFΔARE/WT mouse model
displays similarity with the immune and tissue-related pheno-
type of human CD ileitis. The authors employed non-targeted
1H NMR spectroscopy and targeted LC–MS based metabolic pro-
ﬁling techniques in combination with histological, body weight
and composition analysis and fecal energy loss to characterize site
speciﬁc and systemic metabolic phenotypes along CD-like ileitis
development. The results describe different biological processes
associated to the disease onset, including modiﬁcations of the
general cell membrane composition, energy homeostasis loss,
and higher levels of inﬂammatory lipid mediators (cytokines
and eicosanoids). Tissue pathology was associated with local
expression of pro-inﬂammatory cytokines (i.e., TNF, IFNγ, and
IL-6) and increased concentrations of cholesterol, plasmalogens,
sphingomyelins, glycerophospholipids, and PUFAs. The authors
suggested that lipid accumulation could be subsequent to the
reported massive immune cell inﬁltration leading to an alter-
ation of the overall lipid membrane composition. CD-induced
alterations of cholesterol and PUFAs levels could be associated to
relative changes in lipid rafts of intestinal epithelial cellswith possi-
ble implication in the increased paracellular permeability reported
in the pathophysiology of CD.Taken together, this new set of meta-
bolic ﬁndings on IBD in both pre-clinical and clinical studies could
be used to generate mechanistic hypotheses on the intimate cross
talk between inﬂammation, gut microbiota, and host metabolism
that is ultimately foreseen to lead to new early onset biomarkers
and therapeutic targets and solutions.
Irritable bowel syndrome is anothermajormultifactorial diges-
tive disorders affecting around 20% of the industrialized adult
population for which underlying mechanisms must be further
elucidated (Loftus Jr., 2004). The pathology is generally associated
to a broad range of symptoms including abdominal pain, bowel
habit disturbance, changes in stool frequency and consistency. The
role of abnormal microbiota composition in the pathogenesis of
IBS is also supported by clinical and experimental data (Madden
and Hunter, 2002; Si et al., 2004; Malinen et al., 2005; Matto et al.,
2005) although causal relationships with IBS development is not
yet established.Attemptwasmade to study IBSwith a combination
ofmicrobial andmetabolomic outcomes using stool analysis (Pon-
nusamy et al., 2011). Using a GC–MS methodology, the authors
highlighted higher levels of speciﬁc amino acids (alanine and
pyroglutamate) and phenolic compounds (hydroxyphenyl acetate
and hydroxyphenyl propionate) with IBS. The authors associ-
ated these metabolic changes of protein and carbohydrate energy
metabolism in the gut with alterations of speciﬁc gut microbial
populations, including the abundance of lactobacilli and Clostrid-
ium. Martin et al. (2006) employed a NMR-based metabolomics
of plasma, jejunal wall, and myenteric plexus–longitudinal mus-
cle tissues collected from a post-infective IBS model to assess
molecular changes in relation to the disease and nutritional inter-
ventions. Post-infective IBS was associated with a modiﬁcation
of energy metabolism to meet the energy requirements due to
the intestinal muscular hyper-contractility, as noted with changes
in energy metabolic intermediates, lipid, and amino acid metab-
olism. In addition, the jejunal wall tissues showed variations in
the levels of gut microbiota-related metabolites that were corre-
lated to the disruption of the gut microbiota observed in IBS. This
study also conﬁrmed the role of Lactobacillus paracasei probiotics
in normalizing the muscular activity and the disturbed energy
metabolismmodulating glycogenesis and lipid oxidation. In addi-
tion, the effects of the probiotic L. paracasei and L. paracasei-free
spent culture medium on the IBS mouse model were also evalu-
ated. Treating the mice with L. paracasei probiotics alleviated gut
muscle hyper-contractility and normalized the levels of immune
markers suggesting amelioration of the inﬂammatory response
(Verdu et al., 2004).
Celiac disease (CeD) is another multifactorial gastrointesti-
nal disorder strongly associated with speciﬁc dietary features,
which have both genetic and environmental determinants. CeD
is broadly deﬁned as an immune-mediated enteropathy induced
in response to the ingestion of wheat gluten or related rye and
barley proteins in genetically susceptible individuals. Bertini et al.
(2009) demonstrated that combinatorial metabolomic analysis of
blood sera and urine could help further the understanding of
CeD. The metabolomic analysis of the bioﬂuids collected from
34 CeD patients and 34 healthy controls. The classiﬁcation accu-
racy of CeD and healthy control groups was 79.7–83.4% for
serum and 69.3% for urine. CeD was associated with a signiﬁcant
reduction of the circulating levels of amino acids, lipids, pyru-
vate, and choline, and increased levels of glucose and the ketone
body 3-hydroxybutyric acid, which described a major alteration
of energy homeostatic regulation. Moreover, the urine meta-
bolic signature provided a complementary description of meta-
bolic processes under the inﬂuence of the gut microbial changes
induced by CeD, marked by altered urinary excretion of indoxyl
sulfate, meta-hydroxyphenylpropionate, and phenylacetylglycine.
The highlighted changes in gut microbial co-metabolites may be
associated to aberrant microbiota previously characterized in the
small bowel of subjects suffering of CeD (Tjellstrom et al., 2005).
CLINICAL APPLICATIONS FOR METABOLIC SYNDROME AND
BARIATRIC SURGERY
The world wide pandemic rise of obesity prevalence is strongly
linked to incidence of type 2 diabetes (T2D) and cardiovascu-
lar disorders. Recently, Newgard et al. (2009) have described a
branched chain amino acids (BCAAs) related metabolic signa-
ture contributing to insulin resistance in obese human subjects.
Furthermore, Suhre et al. (2010) recently applied metabolomic
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analyses to the study of an epidemiological cohort in which
diabetes-related complications could be detected already under
sub-clinical conditions. In addition to previously reported T2D
biomarkers, including sugar metabolites, ketone bodies, and
BCAA, metabolites resulting from perturbations of metabolic
pathways linked to kidney dysfunction (3-indoxyl sulfate), lipid
metabolism (glycerophospholipids, free fatty acids), and bile acid
metabolism. Moreover, metabolomics was employed to decipher
indicators of early onsets of pre-diabetes status, marked by alter-
ations in fatty acid, tryptophan, uric acid, bile acid, and gut
microbial metabolism (Zhao et al., 2010). Furthermore, non-
alcoholic fatty liver disease (NAFLD) is increasingly considered
as a main pathological determinant in various obesity and insulin
resistance related diseases (Johnson et al., 2008; Fabbrini et al.,
2010), with metabolomics and lipidomics being of great poten-
tial to further the understanding of disease etiology and pro-
gression. For instance, a remarkable study by Barr et al. (2010)
integrated the analysis of human sera from non-diabetic, mor-
bidly obese, biopsy-proven NAFLD patients, and a NAFLDmouse
model. The study demonstrated reduced levels of creatine and
increased concentrations in bile acids and eicosanoids associated
with liver dysfunctions. More recently, metabolomics was suc-
cessfully employed to demonstrate a relationship between gut
microbial metabolism of dietary phosphatidylcholine and cardio-
vascular pathogenesis in humans (Wang et al., 2011). In partic-
ular, Wang et al. described how the circulating levels of choline,
trimethylamine-N -oxide, and betaine were shown to predict the
risk for cardiovascular events, which offers novel perspectives for
therapeutical and nutraceutical approaches. Existing therapeutic
strategies to obesity lies in changing dietary habits and lifestyle
or pharmacotherapies, yet, with only marginally beneﬁcial effects
for morbidly obese patients. In such a context, bariatric surgery
appears as an efﬁcient therapeutic approach to counteract type
2 diabetes and morbid obesity (Li et al., 2011a,b). Nevertheless,
if bariatric surgery clearly leads to rapid improvement in glucose
metabolism, the molecular mechanisms of this so-called “meta-
bolic surgery” remain poorly understood (Li et al., 2011a,b). Li
et al. (2011a) have reported ametabolomic study in non-obese rats
recovering from bariatric surgery. Intriguingly, substantial shifts
of the main gut bacteria phyla toward higher concentrations of
Proteobacteria, and lower concentrations of Firmicutes and Bac-
teroidetes in comparison with sham-operated rats were reported.
Bariatric surgery was associated with profound alterations of gut
microbial metabolism as noted by changing fecal and/or urinary
levels of bile acids, amines, and cresols. Moreover, increased pro-
tein putrefaction was suggested by the concomitant changes in
decreased tyrosine and increased putrescine and diaminoethane
in feces. These changes in the gut functional ecology were asso-
ciated with a modulation of the energy metabolism, as evidenced
by a decreased urinary excretion of several intermediates of Krebs
cycle.
Bariatric surgery also suggested the induction of a cytotoxic
chemical environment in the gut content in pre-clinical studies
(Li et al., 2011b). The fecal extracts obtained from rats after Roux-
en-Y gastric bypass (RYGB) showed a high toxicity to rodent cells
(mouse lymphoma cell line) when compared to sham-operated
animals. The authors associated this toxicity to the gross structure
of the microbiome, which was also strongly correlated with spe-
ciﬁc urinary andmetabolic signatures. The rats after RYGB indeed
showed a very strong alteration of the urinary excretion of gut
bacterial co-metabolites, namely phenylacetylglycine and indoxyl
sulfate in urine and gamma-aminobutyrate, putrescine, tyramine,
and uracil in feces. This profound co-dependent response of mam-
malian and microbial metabolism suggests that RYGB exerts local
and global metabolic effects which may have an inﬂuence on
long-term cancer risk and cytotoxic load.
CLINICAL APPLICATIONS FOR CANCER DIAGNOSIS
Metabolomics is today vastly applied for diseases diagnosis, with
cancer being one of the major applications. Conventional tumor
markers are relatively unsuitable for detecting carcinoma at an
early stage and such novel insights may become critical in the
development of tailored approaches to reduce disease burden.
Using plasma free amino acids proﬁling, Miyagi et al. (2011) pro-
posed a novel diagnostic measurements for lung, gastric, colorec-
tal, breast, and prostate cancer. Cancer patients and controls could
be discriminated using multivariate analysis based on plasma free
amino acids proﬁles. Interestingly, tryptophan was identiﬁed as
one of the most important amino acids in relation to cancer pro-
gression. Ikeda et al. (2011) also investigated serum metabolic
signatures in patients suffering of gastrointestinal cancers. Human
serum samples from esophageal, gastric, and colorectal cancer
(CRC) patients were compared to healthy volunteers. Amongst the
most signiﬁcantly altered metabolites, malonate, and serine were
speciﬁc to esophageal cancer; 3-hydroxypropionate and pyruvate
for gastric cancer and alanine, glutamine, and glucuronic lactone
for CRC.Very recently, Song et al. (2011a,b) appliedmetabolomics
to both sera and tissues biopsies to investigate biomarkers of gastric
cancer that could help predicting carcinogenesis and metastasis at
an early stage. Their analysis of biopsies using a GC–MS approach
provided a set of 15 metabolites associated with the gastric cancer
morbidity (Song et al., 2011a). This metabolic signature encom-
passed signiﬁcant alterations of glycolysis, fatty acid oxidation,
cholesterol, and amino acid metabolism (Song et al., 2011a). A
similar approachwas applied tomonitor serummetabolic compo-
sition of gastric cancer patients, which conﬁrmed these metabolic
alterations in addition to nucleotide metabolism at systemic level
(Song et al., 2011b).
Colorectal cancer, a very common cause of cancer morbidity,
particularly suffers from the absence of non- orminimally invasive
diagnostics for early detection. Over 1 million cases of CRC are
diagnosed each year worldwide making it one of the most spread
cancer type (Cunningham et al., 2010). CRC is responsible for
approximately 529,000 deaths each year, 60%of those occurring in
developed countries (Goldberg,2005).Numerous studies reported
that the general population of intestinal bacteria is associated
with initiation of colon cancer via the production of carcinogens,
co-carcinogens, or pro-carcinogen substances (O’Keefe, 2008).
Recently, Ritchie et al. (2010a) applied metabolomics to study
CRC in American and Japanese populations using MS analyses
of serum samples. Comprehensive metabolomic analyses revealed
signiﬁcantly reduced levels of 28–36 carbon-containing hydrox-
ylated polyunsaturated ultra long-chain fatty acids (hPULCFAs).
Structure elucidation studies on the C28 molecules revealed two
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molecular families harboring two or three hydroxyl groups and
various unsaturation levels. The authors discussed the sensitivity
and speciﬁcity of these putatively newCRC serummarkers regard-
less of ethnic or geographic background. In a follow-up study,
the authors investigated the effect of CRC therapy on the serum
level of hPULCFAs (Ritchie et al., 2010b). The analyses indicated
that the circulating levels of these hPULCFAs were not affected
by conventional CRC treatment and hypothesized the occurrence
of these markers in early stage of CRC development. 1H NMR
spectroscopy was also applied to attempt to characterize the meta-
bolic signature of malignant colon mucosa. Signiﬁcant increased
levels of taurine, choline-containing compounds, and lipids were
reported inmalignant tissues (Moreno et al., 1993). More recently,
a proteomic study (Bi et al., 2006) reported alterations of multi-
ple metabolic pathways namely purine and pyrimidine, glycolysis,
gluconeogenesis, glucuronic acid synthesis, and tricarboxylic acid
cycle also occur in CRC tissue samples. Chan et al. (2009) com-
pared the metabolic proﬁle of biopsied colorectal tumors and
their matched normal mucosa obtained from 31 CRC patients
using high-resolution magic angle spinning–NMR and GC–MS
and obtained 31 marker metabolites that were able to distinguish
normal from malignant samples and further colon from rectal
cancers. These metabolic alterations were associated with CRC-
inducedmetabolic perturbations such as increased tissue hypoxia,
glycolysis, nucleotide biosynthesis, lipid metabolism, inﬂamma-
tion, and steroid metabolism. Moreover, the application of NMR
metabolic proﬁling to fecal water extracts has interesting poten-
tial as a diagnostic tool for detecting CRC (Monleon et al., 2009).
NMRmetabolic proﬁles of fecal water extracts from CRC patients
were markedly distinct from controls with lower concentrations
of SCFAs (acetate and butyrate) and higher levels of proline and
cysteine, the later being two major components of most colonic
epithelium mucus glycoproteins.
METABOLIC ASSESSMENT OF PROBIOTICS, PREBIOTICS,
AND SYNBIOTICS NUTRITIONAL INTERVENTIONS:
UNDERSTANDING THE MOLECULAR FOUNDATIONS OF GUT
MICROBIAL–MAMMALIAN METABOLIC INTERACTIONS FOR
DISEASE PREVENTION
Food products are nowadaysmore andmore commonly employed
to modulate the composition of the gut microbiota with the main
objective to prevent disease development and contribute to the
health status’maintenance.The effects of consuming livemicrobial
supplements (probiotics) on themicrobial ecology, and on human
health and nutritional status have been extensively investigated
over the past years (Collins and Gibson, 1999). Probiotic supple-
mentation aims at replacing or reducing the number of potentially
pathogenic bacteria in the intestine by enriching the populations
of beneﬁcial strains that ferment carbohydrates and that have lit-
tle proteolytic activity. As an alternative, prebiotics, non-digestible
food ingredients, generally oligosaccharides, modify the balance
of the intestinal microbiota by stimulating the activity of health
beneﬁcial bacteria, such as lactobacilli and biﬁdobacteria (Gib-
son and Roberfroid, 1995; Collins and Gibson, 1999). Eventually,
the combined use of prebiotics and probiotics, also called syn-
biotics, may offer superior effects in health maintenance through
modulating themicrobial functional ecology (Collins and Gibson,
1999; Schrezenmeir and de Vrese, 2001). Nowadays, clinical trials
support the claims of efﬁcacy of pro- and prebiotic nutritional
intervention with regard to various proposed beneﬁcial health
effects, and this has raised the requirement for providing addi-
tional evidence and for elucidation of the molecular bases of their
action. This can only be captured effectively by studying the global
system response of an organism to an interventionusing top-down
systems biology approaches, as commented above under various
gastrointestinal conditions. Such investigations can be conducted
using germfree and gnotobiotic animals to evaluate the effects on
host functions after colonizing the gut with a single microbial
species (Falk et al., 1998). Martin et al. (2007b) employed such an
approach to generate a region-speciﬁc metabolic mapping of the
gut tract of a gnotobiotic mouse, in which they assessed the effects
of mouse supplementation with L. paracasei. Colonization with
live L. paracasei induced region-dependent changes in the meta-
bolic proﬁles of all intestinal tissues, except for the colon,consistent
with modulation of intestinal digestion, absorption of nutrients,
energy metabolism, lipid synthesis, and protective functions. The
results demonstrated the importance of the transgenomic meta-
bolic interactions between L. paracasei and the host to modulate
the gut functions.
In a series of related studies (Martin et al., 2008a,b, 2009b),
probiotics effects were assessed on the mammalian metabolism
using humanized mouse models. In a ﬁrst study, integration of
metabolic changes across diversemetabolic compartments includ-
ing bioﬂuids, tissues, and cecum levels of SCFAs in relation to
microbial population modulation generated a novel top-down
systems biology view of the host response to probiotic inter-
vention (Martin et al., 2008b). Probiotic exposure resulted in
altered hepatic lipid metabolism coupled with lowered plasma
lipoprotein levels and apparent stimulated glycolysis in animals
harboring a non-adapted gut microbiota. Probiotic treatments
also altered a diverse range of pathways outcomes including amino
acid metabolism, methylamines, and SCFAs. In a second study, it
is the combination of probiotics (L. paracasei or L. rhamnosus),
and two galactosyl-oligosaccharide prebiotics on themicrobiome–
mammalian metabolic interactions that was investigated (Martin
et al., 2008a). The nutritionally induced microbial changes were
associated with the modulation of a range of host metabolic path-
ways,namely gluconeogenesis, lipid, amino acid, andmethylamine
metabolism associated to different bacterial fermentation of car-
bohydrates. Finally, as envisioned through the complex arrays of
host metabolic functions impacted by the nature and the activity
of our gut microbiota, Martin et al. (2009a) described that the
modulation of gut microbial metabolic function using pro-, pre-,
or synbiotics results in signiﬁcant perturbations in the metabolic
pathways across the many individual biological compartments of
a mammalian organism. In particular, they reported, using an
extensive multi-compartmental modeling approach with meta-
bolic imprints from 10 tissue/ﬂuid samples that induced micro-
bial changes affected host lipids, carbohydrates, and amino acids
metabolism in every major mammalian biological analyzed com-
partment. These studies has showed the breadth and the depth of
gutmicrobiomemodulations of the intestinalmetabolite pathways
and indicate that metabolomics combined with key physiologi-
cal indicators is a powerful and reliable approach to tackle the
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challenge to understand the molecular foundations of the beneﬁ-
cial or detrimental role of gut microbiota for health and disease
prevention. Current scientiﬁc evidence, from pre-clinical studies,
suggests that probiotic supplementation may appear as an poten-
tial nutritional solution to contribute to reducing tumor occur-
rence and precancerous lesions in the colon (Shahani and Ayebo,
1980). For instance, recent studies on the rat–azoxymethanemodel
(Le Leu et al., 2005) displayed that the synbiotic combination of
prebiotics and Biﬁdobacterium lactis probiotics signiﬁcantly pro-
tected against the development of CRC. The study demonstrated
that ingested prebiotics acted as a preferential metabolic substrate
that enabled the selective growth of B. lactis and signiﬁcantly con-
tributed to exert its pro-apoptotic action. Because the synbiotic
combination of these agents facilitates the apoptotic response to
DNA damage by a cancer initiator in the colon of rats, the authors
suggested that this warrants further study for its capacity to protect
against CRC.
CONCLUSION: METABOLOMICS, BIOMARKERS, AND
GASTROINTESTINAL DISEASES
This non-exhaustive reviewon state-of-the art approaches tomon-
itor changes in metabolite pattern demonstrate how powerful
systems biology approaches are for assessing the clinical char-
acteristics of gastrointestinal disorders. The current revolution
in nutrigenomics sciences will at term offers new opportunities
for preventive medicine, prognostic strategies and personalized
healthcare, and nutritional management solutions. The rise in
multifactorial disorders (e.g., IBS, IBD), the lack of understand-
ing on the molecular processes at play (bariatric surgery) and
the needs for disease prediction in asymptomatic conditions are
some of the many questions that system biology approaches
are well suited to address. Achieving this goal lies in our abil-
ities to model and understand the complex web of metabolic
interactions between genetics, metabolism, environmental fac-
tors, lifestyle, and nutrition. By opening a direct biochemical
window into the metabolome, metabolomics is a unique sci-
ence perfectly suited for the identiﬁcation of biomarkers capable
of providing better understanding of these complex metabolic
phenomena. In such a context, new concepts joining biomark-
ers development and health monitoring are increasingly recog-
nized as plausible strategies to provide new health oriented solu-
tion to the general population. In particular, major advances in
immunology, metabolomics, and microbial ecology have shown
that the contribution of the intestinal microbiota to the over-
all health status of the host has been so far underestimated.
Through the rigorous characterization of interactions between
the diet and the microbiota, metabolomics is providing new ven-
tures for modulating the microbiota toward the improvement
of human health. The prospective of preventing the progres-
sion of human diseases, by normalizing their effects, by speciﬁc
nutritional intervention programs, such as probiotic supplemen-
tation, could beneﬁt from the applications of nutrigenomics sci-
ences for therapeutic surveillance and assessment of treatment
efﬁcacy.
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